To selectively inactivate STAT3, we employed a cell screening model to identify the small molecule, CIB-6, which specifically inhibits STAT3 activation without affecting STAT1/2 and highlight the potential of using IFN in a combination anti-cancer therapy. The gene discussed is STAT1; the disease is cancer.